

### TEPEZZA (teprotumumab) PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Tepezza (teprotumumab)** are available on the DHS Pharmacy Services website at  
<https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx>.

<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/State/Zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

### CLINICAL INFORMATION

Drug requested: <input type="checkbox"/> Tepezza 500 mg vial <input type="checkbox"/> Tepezza _____	Beneficiary's weight (kg):
Dose/directions: <input type="checkbox"/> 10 mg/kg (_____ mg) for 1 <sup>st</sup> infusion <input type="checkbox"/> 20 mg/kg (_____ mg) every 3 weeks x 7 add'l doses <input type="checkbox"/> other: _____	# of vials requested:
	Refills:
Diagnosis ( <i>submit documentation</i> ):	Dx code ( <i>required</i> ):
<b>SPECIALTY PHARMACY DRUG PROGRAM:</b> Tepezza is included in the DHS Specialty Pharmacy Drug Program and is available from DHS's specialty pharmacy. Refer to <a href="https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Specialty-Pharmacy-Program.aspx">https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Specialty-Pharmacy-Program.aspx</a> for more information about the Specialty Pharmacy Drug Program.	<b>DHS specialty pharmacy:</b> Chartwell Pennsylvania, LP Oakdale, PA Phone: 833-710-0211 Fax: 412-920-1869 <a href="http://www.chartwellpa.com">www.chartwellpa.com</a>
Is the medication being prescribed by or in consultation with an endocrinologist, ophthalmologist, or ocular surgeon specializing in the treatment of thyroid eye disease?	<input type="checkbox"/> Yes <i>Submit documentation of consultation, if applicable.</i> <input type="checkbox"/> No
Is the beneficiary receiving multidisciplinary treatment that includes consultation with both endocrinology and ophthalmology specialties?	<input type="checkbox"/> Yes <i>Submit documentation.</i> <input type="checkbox"/> No
Does the beneficiary have a diagnosis of active, moderate-severe thyroid eye disease defined by both of the following? <i>Check all that apply.</i> <input type="checkbox"/> Clinical Activity Score of $\geq 4$ (on a scale of 0 to 7) <input type="checkbox"/> At least one of the following: <input type="checkbox"/> Lid retraction $\geq 2$ mm <input type="checkbox"/> Moderate or severe soft tissue involvement <input type="checkbox"/> Proptosis $\geq 3$ mm above normal values <input type="checkbox"/> Periodic or constant diplopia	<input type="checkbox"/> Yes <i>Submit documentation.</i> <input type="checkbox"/> No

<p>Does the beneficiary have results of recent thyroid function tests showing one of the following?</p> <p><input type="checkbox"/> Beneficiary is euthyroid</p> <p><input type="checkbox"/> Beneficiary has mild hypo- or hyperthyroidism (free T3 and free T4 serum levels &lt;50% above or below normal limits)</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p><i>Submit documentation.</i></p>
<p>Does the beneficiary have a history of trial and failure of or contraindication or intolerance to a systemic corticosteroid?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p><i>Submit documentation.</i></p>

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

<p><b>Prescriber Signature:</b></p>	<p><b>Date:</b></p>
-------------------------------------	---------------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.